Fraud, Arrogance, and Tragedy in the Quest to Cure Alzheimer’s,” Charles Piller looks how the amyloid hypothesis took over ...

Scientists are testing an experimental anti-amyloid antibody in people expected to develop early-onset Alzheimer's.

Explore the potential of monoclonal antibodies in Alzheimer’s treatment, including breakthroughs and challenges in this ...

Research supporting the amyloid hypothesis—the idea that Alzheimer's is caused by a buildup of amyloid plaques in the ...

A complementary drug to combat Alzheimer's disease could target a specific part of the nerve cell protein tau. This is the finding of new research which also offers a better way to measure the effect ...

New serine biomarkers show promise for early Alzheimer's detection, linking tau assemblies to cognitive decline and offering ...

Years before tau tangles show up in brain scans of patients with Alzheimer's disease, a biomarker test developed at the ...

A complementary drug to combat Alzheimer's disease could target a specific part of the nerve cell protein tau.

Leqembi (lecanemab) and Kisunla (donanemab) are proven to slow cognitive and functional decline by 27 and 35%, respectively.

Readers worry that fraud may tarnish the field and slow the race for a cure. Also: Charles Blow’s farewell; treatment for ...

PITTSBURGH (KDKA) — A breakthrough in the fight against Alzheimer's was made by researchers at the University of Pittsburgh, where a test was created to detect the disease in the brain earlier.

The finding may open a whole new world in the study of Alzheimer's disease, said biophysicist Aneta Stefanovska.